Taxus Cardium Pharmaceuticals Stock Gross Profit
CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Taxus Cardium Pharmaceuticals fundamentals help investors to digest information that contributes to Taxus Cardium's financial success or failures. It also enables traders to predict the movement of Taxus Pink Sheet. The fundamental analysis module provides a way to measure Taxus Cardium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taxus Cardium pink sheet.
Taxus |
Taxus Cardium Pharmaceuticals Company Gross Profit Analysis
Taxus Cardium's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Taxus Cardium Pharmaceuticals reported 0.0 of gross profit. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Taxus Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.Taxus Cardium is currently under evaluation in gross profit category among its peers.
Taxus Fundamentals
Return On Asset | -2.62 | |||
Current Valuation | 881.11 K | |||
Shares Outstanding | 64.93 M | |||
Shares Owned By Insiders | 0.21 % | |||
Number Of Shares Shorted | 150.25 K | |||
Price To Book | 3.36 X | |||
Price To Sales | 137.13 X | |||
EBITDA | (458.68 K) | |||
Net Income | (517.9 K) | |||
Cash And Equivalents | 386.03 K | |||
Cash Per Share | 0.01 X | |||
Total Debt | 1.26 M | |||
Debt To Equity | (1.01) % | |||
Current Ratio | 0.08 X | |||
Book Value Per Share | (0.1) X | |||
Cash Flow From Operations | (1.13 M) | |||
Short Ratio | 1.03 X | |||
Earnings Per Share | (0.02) X | |||
Target Price | 2.0 | |||
Beta | -48.52 | |||
Market Capitalization | 64 | |||
Total Asset | 566.98 K | |||
Retained Earnings | (114.05 M) | |||
Working Capital | (3.8 M) | |||
Current Asset | 30.78 K | |||
Current Liabilities | 3.83 M | |||
Net Asset | 566.98 K |
About Taxus Cardium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |